Guidelines for use of antiretroviral therapy for HIV infected individuals in India (ART guidelines 2008)

Journal of Association of Physicians of India

Volumn 56, Issue MAY, 2008, Pages 339-372

  Pujari, Sanjay ^a   Patel, Atul ^a   Joshi, Shashank R ^a   Gangakhedkar, Raman ^a   Kumarasamy, N ^a   Gupta, S B ^a   Guha, Subhasish Kamal ^a   Nag, Nalin ^a   Rewari, Bharat ^a   Satish, K ^a   Soman, Rajeev ^a   Sorabjee, Jehangir ^a   Swaminathan, Soumya ^a   Gogtay, Jaideep ^a   Wanchu, Ajay ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ADULT; AIDS RELATED COMPLEX; ALGORITHM; ANTIVIRAL RESISTANCE; CD4 LYMPHOCYTE COUNT; CLASSIFICATION; DEVELOPING COUNTRY; DISEASE TRANSMISSION; DRUG COMBINATION; DRUG EFFECT; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; MALE; NEWBORN; PRACTICE GUIDELINE; PREGNANCY; REVIEW; TREATMENT REFUSAL; VIRUS LOAD;

ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ALGORITHMS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DEVELOPING COUNTRIES; DISEASE TRANSMISSION, VERTICAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INDIA; INFANT, NEWBORN; MALE; PREGNANCY; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT REFUSAL; VIRAL LOAD;

EID: 43449133040     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (152)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med1998;338:853- 60.
2. Marins JR, Jamal LF, Chen SY, et al. Dramatic improvement in survival among adult Brazilian AIDS patients. AIDS 2003;17:1675-82.
3. Kumarasamy N, Solomon S, Chaguturu SK, et al. The changing natural history of HIV disease: before and after the introduction of generic antiretroviral therapy in southern India. Clin Infect Dis 2005;41:1525-8.
4. Finzi D, Blackson J, Siliciano JD, et al. Latent infection of CD4 cells provide a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999;5:512-17.
5. Mellors JW, Munoz A, Giorji JV, et al. Plasma Viral load and CD4+ lymphocytes as prognostic markers for HIV-1 infection. Ann Inetrn Med 1997;126;946-54.
6. Egger M, May M, Chene G, et al. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002;360:119-29.
7. Coogan MM, Greenspan J, Challacombe SJ. Oral lesions in infection with human immunodeficiency virus. Bull World Health Organ 2005;83:700-6.
8. Greenspan JS, Greenaspan D. The epidemiology of oral lesions of HIV infection in the developed world. Oral Diseases 2002;8 Suppl 2:34-9.
9. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource limited settings: Towards universal access.
10. Smith HV, Corcoron GD. New drugs and treatment for cryptosporidiosis. Curr Opin Infect Dis 2004;17:557-64.
11. Roberts MT. AIDS-associated progressive multifocal leukoencephalopathy. CNS Drugs 2005;19:671-82.
12. Kumarasamy N, Solomon S, Flanigan TP, et al. Natural history of human immunodeficiency virus disease in southern India. Clin Infect Dis 2003;36:79-85.
13. Santos J, Palacios R, Ruiz J, et al. Study of patients diagnosed with advanced HIV in the ART era-OMEGA Cohort. Int J STD AIDS 2005;16:252-5.
14. Pujari S, Patel A, Naik E, et al. Quantitative immunologic response to ART is similar even when initiated late: Experiences from an Indian cohort. 15th World AIDS Conference, Bangkok 2004; CD abstract.
15. Phillips AN, Staszeweski S, Weber R, et al. HIV viral load response to antiretroviral therapy according to baseline CD4 count and viral load. JAMA 2001;286:2560-7.
16. Sterling TR, Chaisson RE, Keruly J, et al. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study. J Infect Dis 2003;188:1659-65.
17. Moore DM, Hogg RS, Yip B, et al. CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/microL. HIV Med 2006;7:383-8.
18. Clayton A, Mughal T. The changing face of HIV-associated lymphoma: what can we learn about optimal therapy inl the post highly active antiretroviral therapy era? Hematol Oncol 2004;22:111-20.
19. Herman ES, Klotman PE. HIV-associated nephropathy: Epidemiology, pathogenesis, and treatment. Semin Nephrol 2003;23:200-8.
20. Schrelbman T, Freidland G. Use of total lymphocyte count for monitoring response to antiretroviral therapy. Clin Infect Dis 2004;38:257-62.
21. Fehr JS, Nicca D, Sendi P, et al. Starting or changing therapy - a prospective study exploring antiretroviral decision-making. Infection 2005;33:249-56.
22. Hightower M, Kallas EG. Diagnosis, antiretroviral therapy, and emergence of resistance to antiretroviral agents in HIV-2 infection: a review. Braz J Infect Dis 2003;7:7-15.
23. Balakrishnan P, Solomon S, Kumarasamy N, et al. Low-cost monitoring of HIV infected individuals on highly active antiretroviral therapy (HAART) in developing countries. Indian J Med Res 2005;121:345-55.
24. Bessesen M, Ives D, Condreay L, et al. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999;28:1032-5.
25. Tuboi SH, Harrison LH, Spinz E, et al. Predictors of Virologic Failure in HIV-1-Infected Patients Starting Highly Active Antiretroviral Therapy in Porto Alegre, Brazil. J Acquir Immune Defic Syndr 2005;40:324-28.
26. Attili VS, Sundar S, Singh VP, et al. Validity of existing CD4+ classification in north Indians, in predicting immune status. J Infect 2005;51:41-6.
27. Mandy FF, Nicholson JK, McDougal JS. Guidelines for performing single platform absolute CD4 T-cell determinations, with CD45 gating for persons infected with human immunodeficiency virus. MMWR 2003;52:1-13.
28. Pujari SN, Dravid A, Naik E, et al. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr 2005;39:199-202.
29. Saghayam S, Chaguturu SK, Kumarasamy N, et al. Lipoatrophy is the predominant presentation of HIV-associated lipodystrophy in southern India. Clin Infect Dis 2004;38:1646-7.
30. Patel AK, Patel K, Patel J. Lactic acidosis in HIV-I infected patients receiving antiretroviral therapy. J Assoc Physicians India 2004;52:666-9.
31. Van Leeuwen R, Katalama C, Murphy RL, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 2003;17:987-99.
32. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999.341:1865-73.
33. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triplenucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004;350:1850-61.
34. Zhang Z, Hamatake R, Hong Z. Clinical utility of current NNRTIs, and perspectives of new agents in the class under development. Antivir Chem Chemother 2004;15:121-34.
35. Riddler SA, Haubrich R, DiRienzo G, et al. A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection: ACTG 5142. Program and abstracts of the XVI International AIDS Conference; August 13-18, 2006; Toronto, Canada. Abstract THLB0204.
36. th Nov 2006.
37. Fortin C, Joly V. Efavirenz for HIV-1 infection in adults: an overview. Expert Rev Anti Infect Ther 2004;2:671-84.
38. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 2004;35:538-9.
39. Imperiale SM, Lanes SZ, Stern JO, et al. The Viramune (nevirapine) hepatic safety project: analysis of symptomatic hepatic events. Antiviral Ther 2002;7:L57.
40. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a iraemiae open-label trial, the 2NN Study. Lancet 2004;363:1253-63.
41. Patel AK, Pujari S, Patel K , et al. Nevirapine Versus Efavirenz Based Antiretroviral Treatment in Naïve Indian Patients : Comparison of Effectiveness in Clinical Cohort. J Assoc Physicina India 2006;54:915-18.
42. Carr A. Antiretroviral therapy for previously untreated HIV-1 infected adults: 2NN, or just one. Lancet 2004;363:1253-63.
43. Ait-Khaled M, Stone C, Amphlett G, et al. NAÏVE3002 International Study Team. M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS 2002;16:1686-9.
44. Gulick RM, Meibohm A, Havlir D, et al. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS 2003;17:2345-9.
45. Squires KE, Gulick R, Tebas P, et al. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naïve individuals with HIV infection: selection of thymidine analog regimen therapy (START 1). AIDS 2000;14:1591-1600.
46. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. JAMA 2004;292:191-201.
47. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz versus zidovudine, lamivudine and efavirenz for HIV. N Engl J Med 2006;354:251-60.
48. Heffelfinger J, Hanson D, Voetsch A, et al. Renal impairment associated with use of tenofovir. Abstract 779, 13th CROI 2006, Denver.
49. Gallant JE, Parish MA, Keruly JC, et al. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse transcriptase inhibitor treatment. Clin Infect Dis 2005;40:1194-8.
50. DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz for the treatment of antiretroviral naïve HIV infected adults: a randomized equivalence trial. Clin Infect Dis 2004;39:1038-46.
51. Maggiolo F, Ripamonti D, Gregis G, et al. Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naïve HIV-1-infected patients. Antivir Ther 2003;8:339-46.
52. Landman R, Thiam S, Canestri A, et al. Long-term evaluation (15 months) of ddI, 3TC and efavirenz once-daily regimen in naïve patients in Senegal: ANRS 12-04/IMEA 011 study. In: Program and abstracts of the 9th Annual Retrovirus Conference; February 24-28, 2002; Seattle. Abstract 458.
53. Brandi CJ, Margot NA, Miller MD. Long-term follow-up of patients taking tenofovir DF with low-level HIV-1 viremia and the K65R substitution in HIV-1 RT. AIDS 2007;21:761-63
54. Gallant JE. Drug resistance after failure of initial antiretroviral therapy in resource-limited countries. Clin Infect Dis 2007;44:447-52
55. Pujari S, Patel A, Eknath N, et al. Effectiveness of generic Fixed dose combinations of HAART for treatment of HIV infections in INDIA. J Acq Immune Def Syndr 2004;37:1566-69
56. th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, California. Abstract 503
57. Hirsch M, Steigbigel R, Staszewski S, et al. A randomized controlled trial of indinavir, zidovudine and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. J Infect Dis 1999;180:659-75.
58. Torti C, Quiros-Roldon E, Regazzi M, et al. Early virological failure after tenofovir + iraemiae + efavirenz combination in HIVpositive patients upon starting antiretroviral therapy. Antivir Ther 2005;10:505-13.
59. rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 16, 2003. (Abstract H-1722a).
60. Moyle G. Double "d" drug danger. AIDS Read 2003;13:15-24.
61. Hill A, Ruxrungtham K, Hanvanvich M, et al. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 2007;8:679-88.
62. Strategies for management of Antiretroviral therapy study group, El SadrWM, Lundgren JD, Neaton JD, et al. CD4 guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-96
63. Etard JF, Ndiyae J, Therirry-Mieg M, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 2006;20:1181-9.
64. Ghani AC, Ferguson NM, Fraser C, et al. Viral replication under combination antiretroviral therapy: a comaprision of four different regimens. J Acquir Immune Defic Syndr 2002;30:167-76.
65. Maggiolo F, Migliorono M, Pirali A, et al. Duration of viral suppression in patients on stable therapy for HIV-1 infection is predicted by plasma HIV-1 RNA level after 1 month of treatment. J Acquir Immune Defic Syndr 2000;25:36-43.
66. Benson CA, Kaplan JE, Masur H, et al. Treating opportunistic infections among HIV-infected adults and adolescents. MMWR 2004;53(RR15):1-154.
67. Kumarasamy N, Vallabhaneni S, Cecelia AJ, et al. Safe Discontinuation of Primary Pneumocystis Prophylaxis in Southern Indian HIV-Infected Patients on Highly Active Antiretroviral Therapy. J Acquir Immune Defic Syndr 2005;40:377-78.
68. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
69. Bangsberg D, Hecht F, CharlebOI's E, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001;15:1-2.
70. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favor different virologic outcomes for patients treated with Nonnucleoside analogs or protease inhibitors. Clin Infect Dis 2005;40:158-63.
71. Nieuwkerk PT, Oort FJ. Self reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: a meta-analysis. J Acquir Immune Defic Syndr 2005;38:445-8.
72. Kumarasamy N, Safren SA, Raminani SR, et al. Barriers and facilitators to antiretroviral medication adherence among patients with HIV in Chennai, India: a qualitative study. AIDS Patient Care STDS 2005;19:526-37.
73. Pujari SN, Sarna A, Sengar A, et al. Adherence to antiretroviral therapy (ART) and it's principal determinants in HIV infected adults in India. 12th Conff on retroviruses and OI, 2005, Boston, abstract no 627.
74. Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 2004;53:4-9.
75. CDC notice on readers: Updated guidelines on the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or non-nucleoside reverse transcriptase inhibitors. MMWR 2004;53:37
76. PI'scitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St John's Wort. Lancet 2000;355:547-8.
77. Roter hand brief Bristol Myers Squibb December 2004.
78. Moyle G. Mechanisms of HIV and nucleoside reverse transcriptase inhibitor injury to mitochondria. Antivir Ther 2005;10 Suppl 2:M47-52.
79. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003;362:22-29.
80. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004;18:1615-27.
81. Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005;19:399-406.
82. French MA, Lenzo N, John M, Mallal SA, McKinnon EJ, James IR, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000;1:107-15.
83. Kumarasamy N, Chaguturu S, Mayer KH , et al. Incidence of Immune Reconstitution Syndrome in HIV/Tuberculosis-Coinfected Patients after Initiation of Generic Antiretroviral Therapy in India. J Acquir Immune Defic Syndr 2004;37:1574-76.
84. Centers for Disease Control and Prevention. Notice to Readers: Acquired Rifamycin Resistance in Persons with Advanced HIV Disease Being Treated for Active Tuberculosis with Intermittent Rifamycin- Based Regimens. MMWR 2002;51:214-5.
85. Sterling TR, Alwood K, Gachuhi R et al. Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS 1999;13:1899-904.
86. Kassim S, Sassan-Morokro M, Ackah A, et al. Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa. AIDS 1995;9:1185-91.
87. El-Sadr WM, Perlman DC, Denning E, Matts JP, Cohn DL. A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. Clin Infect Dis 2001;32:623-32.
88. Moreno S, Podzamczer D, Blazquez R, et al. Treatment of tuberculosis in HIV infected patients: safety and efficacy of concomitant use of ritonavir and rifampicin. In: XIIIth International AIDS Conference, July 9-14, Durban, South Africa, 2000.2:49.
89. Polk RE, Brophy DF, Israel DS, et al. Pharmacokinetic interaction between amprenavir and rifabutin or rifampin in healthy males. Antimicrob Agents Chemother 2001;45:502-8.
90. Robinson P, Lamsom M, Gigliotti M, et al. Pharamcokinetic interaction between nevirapine and rifampin. International Conf on AIDS, 1998, Geneva, Switzerland pg 1115.
91. rd IAS Conference on HIV pathogenesis and treatment, Rio 2005, abstract no. WePe3.3CO2.
92. Patel Atul K, Patel K, Patel J, et al. Study on safety and antiretroviral effectiveness of concomitant use of rifampicin (RMP) and efavirenz in antiretroviral naïve tuberculosis co infected HIV-1 patients in India. J Acquir Immune Defic Syndr 2004;37:1166-69
93. Manosuthi W, Sangkanuparph S, Thakkinstain A, et al. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. AIDS 2005;19:1481-6.
94. th Nov. 2005)
95. Pedral-Samapio D, Alves C, Netto E, et al. Efficacy of efavirenz 600 mg dose in the ARV therapy regimen for HIV patients receiving rifampicin in the treatment tuberculosis. 10th Conference on Retroviruses and Opportunistic Infections, February 2003, Boston, MA. Abstract 784.
96. Hwaken M, Nunn P, Gathua S, et al. Increased recurrence of tuberculosis in HIV-1 infected patients in Kenya. Lancet 1993;342:332-38.
97. Martin-Carbonero L, Soriano V, Valencia E, et al. Increased impact of chronic viral hepatitis on hospital admissions and mortality amongst HIV infected patients AIDS Res and Human Retroviral 2001;17:1467-71.
98. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005;42:615-24.
99. Cooksley W. Treatment with interferons (including pegylated interferons) in patients with chronic hepatitis B. Semin Liver Dis 2004;24 (suppl):45-53.
100. Benhamou, Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001;358:718-23.
101. Xiong S, Yang H, Westland C, et al. Resistance surveillance of HbeAg chronic hepatitis B patients treated for two years with adefovir dipivoxil. [Abstract]. Hepatology 2003;194(Suppl 2):182.
102. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterol 2003;125:292-7.
103. Bonacini M Kurz A, Locarnini S, et al. Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient co-infected with HIV. Gastroenterology 2002;122: 244-5.
104. Den Brinker M, Wit F, Wertheim-van Dillen PME, et al. Hepatitis B and C virus co-infection and the hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000;14:2895-2902.
105. Martinez E, Blanco JL, Arnaiz JA, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001;15:1261-68.
106. Sulkowski MS. Thomas DL, Mehta SH, et al. Hepatoxicity associated with nevirapine of efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002;35:182-89.
107. Benhamou Y Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C coinfected patients. Hepatology 1999;30:1054-58.
108. Lesens O Deschenes M, Steben M, et al. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis 1999;79:1254-58.
109. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-50
110. Carrat F, Bani-Sadr, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004;292:2839-48.
111. Chung R, Anderson J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-co-infected persons. N Engl J Med 2004;351:451-9
112. Soriano V, Puoti M, Bonacini M, et al. Care of patients with hepatitis C and HIV co-infection. AIDS 2004;18:1-12.
113. Rockstroh JK, Spengier U. HIV and hepatitis C virus coinfection. Lancet Infectious Dis 2004;4:437-44.
114. Breast-feeding and HIV transmission study group. Late post natal transmission of HIV-1 in breast fed children: an individual patient meta-analysis. J Infect Dis 2004;189:2154-66.
115. Tarantal AF, Castilo O, Ekert JE, et al. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys. J Acquir Immune Defic Syndr 2002;29-107-20.
116. Guay LA, Mosoke P, Fleming T, et al. Intrapartum and neonatal single dose iraemiae compared with zidovudine for prevention of MTCT of HIV-1 in Kampala, Uganda: HIVNet 012 randomized trial. Lancet 1999;354:795-802.
117. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum Exposure to Nevirapine and Subsequent Maternal Responses to Nevirapine-Based Antiretroviral Therapy. N Engl J Med 2004;351:229-240.
118. Moodley J, Moodley D. Management of human immunodeficiency virus infection in pregnancy. Best Practice & Research Clinical Obstetrics & Gynaecology 2005;19:169-83.
119. th Conf retroviruses and opportunistic infections, Seattle. Abstract no. 795-W.
120. th Conf Retroviruses and opportunistic infections, Los Angeles Abstract no 740.
121. th Conf Retroviruses and opportunistic infections, Los Angeles Abstract no 739.
122. th Conf Retroviruses and opportunistic infections, Los Angeles Abstract no 741
123. th Conf Retroviruses and opportunistic infections, Los Angeles Abstract no 742
124. Szyld EG, Warley EM, Freimanis L, et al. Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth. AIDS 2006;20:2345-53
125. th 2005)
126. Lallemant M, Jourdain G, Le Couer S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-tochild transmission of HIV-1 in Thailand. N Engl J Med 2004;351:217-28.
127. Read J, Newell M. Efficacy and safety of cesarean delivery for prevention of mother-to-child transmission of HIV-1. Cochrane Database Syst Rev 2005;4:CD005479
128. th Conf on retroviruses and opportunistic infections 2004, San Francisco. Abstract no.99.
129. Iliff PJ, Piwoz EG, Tawengwa NV, et al. Early exclusive breastfeeding reduces the risk of postnatal HIV-1 transmission and increases HIV-free survival. AIDS 2005;19:699-708.
130. Phadke MA, Gadgil B, Bharycha KE, et al. Replacement-fed infants born to HIV-infected mothers in India have a high early postpartum rate of hospitalization. J Nutr 2003;133:3153-7.
131. Mocroft A, Youle M, Moore A, et al. Resonas for modification and discontinuation of antiretrovirals: results from a single treatment center. AIDS 2001;15:185-94.
132. Fatenkeheur G, Romer K, Cramer P, et al. High rates of changes of first antiretroviral combination regimen in an unselected cohort of HIV-1 infected patients. 8th ECCAT 2001, Greece, abstract no 50.
133. Moyle G, Baldwin C, Langroudi B, et al. A 48 week randomized, open label comparision of three abacavir based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr 2003;33:22-28.
134. th Conf on retroviruses and opportunistic infections 2005, Boston abstract no 44B.
135. Kantor R, Shafer RW, Follansbee S, et al. Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS 2004 ;18:1503-11.
136. Skalar PA, Ward DJ, Baker RK, et al. Prevalence and clinical correlates of HIV iraemia ('blips') in patients with previous suppression below the limits of quantification. AIDS 2002;16:2035-41.
137. Moore DM, Hogg RS, Yip B, et al. Discordant Immunologic and Virologic Responses to Highly Active Antiretroviral Therapy Are Associated With Increased Mortality and Poor Adherence to Therapy. J Acquir Immune Defic Syndr 2005;40:288-93.
138. th Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2004 abstract no. 817.
139. Braitstein P, Asselin J, Montessori V, et al. Impact of the hepatitis C virus on CD4 response post initiation of highly active antiretroviral therapy among a population-based HIV treatment cohort. International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France 2003 abstract 161.
140. Zang Z, Hamatake R, Hong Z. Clinical utility of current NNRTIs and perspectives of new agents in this class under development. Antivir Chem Chemother 2004;15:121-34.
141. Ulrik BD, Jan G, Mike Y, et al. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. Antivir Ther 2005;10:735-43.
142. Dragstead UB, Gerstoft J, Pedersen C, et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. I Infect Dis 2003;188:635-42.
143. Shafran SD, Mashinter LD, Roberts SE. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med 2005;6:421-5.
144. deMendoza C, Soriano V. Resistance to HIV protease inhibitors: mechanisms and clinical consequences. Curr Drug Metab 2004;5:321-8.
145. Turner D, Brenner BG, Routy JP, et al. Rationale for maintenance of the M184V resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients. New Microbiol 2004;27(2 Suppl 1):31-9.
146. Underwood M, St Clair M, Ross L, et al. Cross resistance of clinical samples with K65R, L74V, and M184V mutations. !2th conf retroviruses and opportunistic infections 2005, Boston abstract no 714
147. Mouroux M, Descamps D, Izopet J ,et al. Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naïve patients receiving stavudine plus lamivudine combination therapy. Antivir Ther 2001;6:179-83.
148. Antoniou T, Park Wyllie L, Tseng AL. Tenofovir: A nucleotide analog for the management of HIV infection. Pharmacotherapy 2003;23:29-43.
149. White KL, Margot NA, Ly JK, et al. A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT. AIDS 2005;19:1751-60.
150. th Conf on retroviruses and opportunistic infections 2001, Chicago abstract no 434.
151. CDC, Updated U.S. Public health services guidelines for the management of occupational exposures to HIV and recommendations for Post exposure prophylaxis. MMWR 2005;54:RR9:1-17.
152. Bell DM. Occupational risk of human immunodeficiency virus infection health care workers: An overview. Am J Med 1997;102:9-15.